ViiV Healthcare Expands Access to Long-Acting HIV Prevention
ViiV Healthcare, renowned for its commitment to HIV solutions, is stepping up its efforts significantly by pledging to provide an increased supply of long-acting HIV pre-exposure prophylaxis (PrEP). This ambitious plan aims to deliver more than two million doses of cabotegravir, also known as CAB LA, for the years 2025-2026. This figure represents a threefold increase compared to its supply in 2024, aimed at accelerating access to those who face the greatest challenges in managing HIV.
Commitment to Global Health
During the unveiling of this initiative, key figures at ViiV stressed the importance of expanding access alongside addressing the pressing needs of HIV-affected communities. Deborah Waterhouse, the Chief Executive Officer at ViiV Healthcare, emphasized their ongoing commitment to integrating CAB LA into global efforts that champion health equity and accessibility. The focus will be particularly on the populations that experience disproportionate rates of HIV infection, with a keen eye on the needs of young women and girls in vulnerable regions.
To successfully implement this strategy, ViiV is poised to work closely with local and international partners to ensure seamless integration of CAB LA into existing healthcare structures. This collaborative effort is designed to bolster the efficiency of HIV prevention programs in low- and middle-income countries.
Rapid Roll-Out of CAB LA for PrEP
The rollout of CAB LA for PrEP has been notably swift, particularly in Sub-Saharan Africa where the HIV epidemic is most pronounced. Following regulatory approvals from health authorities, including the U.S. FDA, CAB LA has begun to see implementation in several countries. In February 2024, Zambia was the first to introduce this long-acting preventive measure, with subsequent implementations occurring in nations like Malawi and Zimbabwe. By the end of 2024, ViiV anticipates that its CAB LA supply will be spread across 14 countries, fostering a rapid response to HIV prevention.
Strategies for Affordability and Accessibility
Recognizing that cost can be a significant barrier to access, ViiV Healthcare is committed to making CAB LA available at a non-profit price in low-resource settings. This approach is supplemented by a licensing agreement established with the Medicines Patent Pool, aimed at facilitating the development of generic versions of CAB LA. ViiV is actively working with generic manufacturers to expedite this process, ensuring that affordable options for HIV prevention become readily available.
Understanding Apretude
Apretude, the commercial name for CAB LA, has made significant strides in regulatory approval, being recognized in 53 countries across 24 different agencies. This accomplishment demonstrates the high level of confidence in CAB LA’s effectiveness as a preventive measure against sexually transmitted HIV-1 infection. For individuals and communities at high risk, Apretude offers an essential option that works best in conjunction with safer sex practices.
About ViiV Healthcare and GSK
ViiV Healthcare was founded in November 2009 with the intent of advancing treatment and care for individuals living with HIV. The company acts with a mission to bring forward innovative medicines and robust support for communities affected by HIV. As a part of this effort, ViiV’s parent company, GSK, plays an instrumental role in the global biopharma landscape, utilizing its resources to further scientific advancements in disease treatment.
As ViiV continues to expand its outreach, the commitment to tackling HIV through innovative solutions and partnerships remains at the forefront of its operations. For comprehensive insights into ViiV Healthcare’s work, interested parties are encouraged to visit their official website.
Frequently Asked Questions
What is CAB LA for PrEP?
CAB LA for PrEP is a long-acting injectable medication designed to help prevent HIV infection in individuals at high risk.
How does ViiV Healthcare plan to expand access?
ViiV Healthcare plans to triple its supply of CAB LA to over two million doses, specifically targeting low- and middle-income countries.
What communities will benefit from this initiative?
The initiative focuses primarily on populations with the highest unmet needs, notably young women and girls in areas highly affected by HIV.
Which countries are involved in CAB LA roll-out?
The roll-out is set to reach a total of 14 countries, including Zambia, Malawi, Zimbabwe, Eswatini, and Ukraine.
How does ViiV ensure affordability?
ViiV provides CAB LA at a non-profit price and collaborates with organizations to develop affordable generic versions.
